News

Following the re-introduction of the H.R. 3 drug pricing legislation, Rich Masters -- Chief Public Affairs and Advocacy Officer of  the Biotechnology Innovation Organization (BIO) -- made the following remarks: "On behalf of BIO’s…

Dr. Michelle McMurry-Heath, president and CEO of the Biotechnology Innovation Organization (BIO), yesterday sent a letter to U.S. Trade Representative (USTR) Ambassador Katherine Tai sharing BIO perspectives regarding the proposed WTO “TRIPS waiver”…

Dear Secretary Buttigieg, National Climate Advisor McCarthy, and Director Deese: The undersigned organizations, representing aviation industry stakeholders including passenger and cargo carriers, business and general aviation, aircraft and engine…

On Tuesday, April 6th, BIO submitted comments on the U.S. Food and Drug Administration (FDA)’s January 2021 draft industry guidance on “Human Gene Therapy for Neurodegenerative Diseases.” In its comments, BIO stated that while the guidance covers…

BIO files amicus brief in support of a petition for rehearing related to patent-eligibility of diagnostic technology. 

BIO files an Amicus Brief on rehearing by the Precedential Opinion Panel of the Patent Trial and Appeal Board.